Advances in preclinical and clinical studies of oncolytic virus combination therapy
Oncolytic viruses represent a distinct class of viruses that selectively infect and destroy tumor cells while sparing normal cells. Despite their potential, oncolytic viruses encounter several challenges as standalone therapies. Consequently, the combination of oncolytic viruses with other therapeut...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-02-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1545542/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1825206807922999296 |
|---|---|
| author | Wenlong Du Jintong Na Liping Zhong Liping Zhong Pumin Zhang |
| author_facet | Wenlong Du Jintong Na Liping Zhong Liping Zhong Pumin Zhang |
| author_sort | Wenlong Du |
| collection | DOAJ |
| description | Oncolytic viruses represent a distinct class of viruses that selectively infect and destroy tumor cells while sparing normal cells. Despite their potential, oncolytic viruses encounter several challenges as standalone therapies. Consequently, the combination of oncolytic viruses with other therapeutic modalities has emerged as a prominent research focus. This paper summarizes the tumor-killing mechanisms of oncolytic viruses, explores their integration with radiotherapy, chemotherapy, immune checkpoint inhibitors, CAR-T, and CAR-NK therapies, and provides an overview of related clinical trials. By synthesizing these advancements, this study seeks to offer valuable insights for the clinical translation of oncolytic virus combination therapies. |
| format | Article |
| id | doaj-art-9bca6bffefec491ba196c16ae54ed349 |
| institution | Kabale University |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-9bca6bffefec491ba196c16ae54ed3492025-02-07T05:10:34ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-02-011510.3389/fonc.2025.15455421545542Advances in preclinical and clinical studies of oncolytic virus combination therapyWenlong Du0Jintong Na1Liping Zhong2Liping Zhong3Pumin Zhang4State Key Laboratory of Targeting Oncology, National Center for International Research of Bio-targeting Theranostics, Guangxi Key Laboratory of Bio-targeting Theranostics, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Talent Highland of Major New Drugs Innovation and Development, Guangxi Medical University, Nanning, ChinaState Key Laboratory of Targeting Oncology, National Center for International Research of Bio-targeting Theranostics, Guangxi Key Laboratory of Bio-targeting Theranostics, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Talent Highland of Major New Drugs Innovation and Development, Guangxi Medical University, Nanning, ChinaState Key Laboratory of Targeting Oncology, National Center for International Research of Bio-targeting Theranostics, Guangxi Key Laboratory of Bio-targeting Theranostics, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Talent Highland of Major New Drugs Innovation and Development, Guangxi Medical University, Nanning, ChinaPharmaceutical College, Guangxi Medical University, Nanning, Guangxi, ChinaState Key Laboratory of Targeting Oncology, National Center for International Research of Bio-targeting Theranostics, Guangxi Key Laboratory of Bio-targeting Theranostics, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Talent Highland of Major New Drugs Innovation and Development, Guangxi Medical University, Nanning, ChinaOncolytic viruses represent a distinct class of viruses that selectively infect and destroy tumor cells while sparing normal cells. Despite their potential, oncolytic viruses encounter several challenges as standalone therapies. Consequently, the combination of oncolytic viruses with other therapeutic modalities has emerged as a prominent research focus. This paper summarizes the tumor-killing mechanisms of oncolytic viruses, explores their integration with radiotherapy, chemotherapy, immune checkpoint inhibitors, CAR-T, and CAR-NK therapies, and provides an overview of related clinical trials. By synthesizing these advancements, this study seeks to offer valuable insights for the clinical translation of oncolytic virus combination therapies.https://www.frontiersin.org/articles/10.3389/fonc.2025.1545542/fulloncolytic virustumor therapycombined treatmentclinical trialsimmunity |
| spellingShingle | Wenlong Du Jintong Na Liping Zhong Liping Zhong Pumin Zhang Advances in preclinical and clinical studies of oncolytic virus combination therapy Frontiers in Oncology oncolytic virus tumor therapy combined treatment clinical trials immunity |
| title | Advances in preclinical and clinical studies of oncolytic virus combination therapy |
| title_full | Advances in preclinical and clinical studies of oncolytic virus combination therapy |
| title_fullStr | Advances in preclinical and clinical studies of oncolytic virus combination therapy |
| title_full_unstemmed | Advances in preclinical and clinical studies of oncolytic virus combination therapy |
| title_short | Advances in preclinical and clinical studies of oncolytic virus combination therapy |
| title_sort | advances in preclinical and clinical studies of oncolytic virus combination therapy |
| topic | oncolytic virus tumor therapy combined treatment clinical trials immunity |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2025.1545542/full |
| work_keys_str_mv | AT wenlongdu advancesinpreclinicalandclinicalstudiesofoncolyticviruscombinationtherapy AT jintongna advancesinpreclinicalandclinicalstudiesofoncolyticviruscombinationtherapy AT lipingzhong advancesinpreclinicalandclinicalstudiesofoncolyticviruscombinationtherapy AT lipingzhong advancesinpreclinicalandclinicalstudiesofoncolyticviruscombinationtherapy AT puminzhang advancesinpreclinicalandclinicalstudiesofoncolyticviruscombinationtherapy |